These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16111602)

  • 41. High-dose proton beam therapy for Stage I non-small-cell lung cancer.
    Nihei K; Ogino T; Ishikura S; Nishimura H
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):107-11. PubMed ID: 16458447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Nintedanib for the treatment of radiation pneumonitis].
    Dejonckheere CS; Höller U; Käsmann L
    Strahlenther Onkol; 2024 May; 200(5):457-459. PubMed ID: 38421432
    [No Abstract]   [Full Text] [Related]  

  • 43. Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer.
    Liu Y; Yu H; Zhang C; Cheng Y; Hu L; Meng X; Zhao Y
    Eur J Cancer; 2008 Nov; 44(16):2425-32. PubMed ID: 18789680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pathogenesis, diagnostics and treatment of radiation pneumonitis induced by radiotherapy of lung cancer].
    Kiazimov KI
    Georgian Med News; 2009 Sep; (174):115-8. PubMed ID: 19801749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using the differential from complete blood counts as a biomarker of fatigue in advanced non-small-cell lung cancer: an exploratory analysis.
    Paddison JS; Temel JS; Fricchione GL; Pirl WF
    Palliat Support Care; 2009 Jun; 7(2):213-7. PubMed ID: 19538804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
    Anscher MS; Garst J; Marks LB; Larrier N; Dunphy F; Herndon JE; Clough R; Marino C; Vujaskovic Z; Zhou S; Dewhirst MW; Shafman TD; Crawford J
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):477-82. PubMed ID: 16904841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concurrent end-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy.
    Graham PH; Clark C; Abell F; Browne L; Capp A; Clingan P; De Sousa P; Fox C; Links M
    Australas Radiol; 2006 Aug; 50(4):342-8. PubMed ID: 16884421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer.
    Lo SS; Fakiris AJ; Papiez L; Abdulrahman R; McGarry RC; Henderson MA; Forquer JA; Hoopes D; Timmerman RD
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):87-98. PubMed ID: 18095886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
    Tsujino K; Hirota S; Kotani Y; Kado T; Yoden E; Fujii O; Soejima T; Adachi S; Takada Y
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1100-5. PubMed ID: 16373082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Just enough palliation: radiation dose and outcome in patients with non-small-cell lung cancer.
    Wagner H
    J Clin Oncol; 2008 Aug; 26(24):3920-2. PubMed ID: 18711179
    [No Abstract]   [Full Text] [Related]  

  • 53. Transforming growth factor-{beta}: a biomarker in Marfan syndrome?
    Braverman AC
    Circulation; 2009 Aug; 120(6):464-6. PubMed ID: 19635965
    [No Abstract]   [Full Text] [Related]  

  • 54. Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model.
    Millar HJ; Nemeth JA; McCabe FL; Pikounis B; Wickstrom E
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2180-7. PubMed ID: 18708412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum endostatin levels in patients with lung carcinoma.
    Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
    Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
    Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
    Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stereotactic body radiation therapy: a treatment in need of basic biological research.
    Timmerman RD; Story M
    Cancer J; 2006; 12(1):19-20. PubMed ID: 16613657
    [No Abstract]   [Full Text] [Related]  

  • 58. Low incidence of isolated nodal failures after involved-field radiation therapy for non small-cell lung cancer: blinded by the light?
    Jeremic B
    J Clin Oncol; 2007 Dec; 25(35):5543-5. PubMed ID: 17984182
    [No Abstract]   [Full Text] [Related]  

  • 59. Lung cancer may be different for men and women, but researchers ponder what to do?
    Hede K
    J Natl Cancer Inst; 2007 Dec; 99(24):1830-2. PubMed ID: 18073369
    [No Abstract]   [Full Text] [Related]  

  • 60. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.